Skip to content
Sign in
Business opportunities for Pleryon Therapeutics

Compatibility /100

54/100

High potential

Why talk

  1. LOBSTECH likely needs funding — Pleryon Therapeutics can offer investor introductions (inferred from public profile).
  2. Complementary sectors: Biotech & life sciences × Agri & FoodTech — room for a joint offer or co-selling.
  3. LOBSTECH (Indonesia) is a regional neighbour in Asia — a natural first step for cross-border expansion.

Score anatomy

Each segment is what one dimension adds, out of 100.

Needs ↔ offers17.5Market bridge12.5Customer potential8.3Sector synergy12.8Stage complementarity3.0

Dimension by dimension

Needs ↔ offers

17.5 / 35 pts

Pleryon Therapeutics can help LOBSTECH.

  • LOBSTECH likely needs funding — Pleryon Therapeutics can offer investor introductions (inferred from public profile).

Market bridge

12.5 / 25 pts

Regional bridge.

  • LOBSTECH (Indonesia) is a regional neighbour in Asia — a natural first step for cross-border expansion.

Customer potential

8.3 / 15 pts

Some customer potential.

  • LOBSTECH already has first customers in a related sector (Agri & FoodTech): According to the website: capacity of 3,600 lobsters/month for partners, claimed sales of 200 kg/month locally and 1–2 t/month for export,….

Sector synergy

12.8 / 15 pts

Complementary sectors.

  • Complementary sectors: Biotech & life sciences × Agri & FoodTech — room for a joint offer or co-selling.

Stage complementarity

3.0 / 10 pts

Weak stage signal.

  • Stage not comparable (Series A / Undetermined).

How the score works

Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “All goals”: Needs ↔ offers 35, Market bridge 25, Customer potential 15, Sector synergy 15, Stage complementarity 10. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.

Potential blends compatibility (65%) with the mean global score of both startups (35%): 51/100 — high from 50, medium from 36.